Xiao Qin Lu

Xiao Qin Lu currently works at Veru, Inc., as Independent Director from 2021, Inventia Healthcare Ltd., as Director from 2018, Innovative Cellular Therapeutics Co., Ltd., as Chief Operating Officer, Innovative Cellular Therapeutics, Inc., as Chief Operating Officer, and Fortress Biotech, Inc., as Chief Strategy Officer from 2025.
Dr. Lu also formerly worked at Checkpoint Therapeutics, Inc., as Chief Executive Officer from 2014 to 2015, Avenue Therapeutics, Inc., as President, CEO, CFO & Director in 2022, Veru, Inc., as Independent Director from 2016 to 2019, Inventiva SA, as Independent Director from 2018 to 2025, Fortress Biotech, Inc., as Director from 2022 to 2025, Citigroup Global Markets, Inc. (Broker), as Research Analyst, Fortress Biotech, Inc., as CFO, Executive VP & Head-Investor Relations from 2013 to 2017, Broadpoint.Gleacher Securities, as Vice President, Lehman Brothers Global Asset Management, as Analyst from 2001 to 2004, and Lazard Asset Management LLC, as Analyst from 2001 to 2004.
Dr. Lu received her Masters Business Admin degree from The Leonard N Stern School of Business, doctorate degree from New York University School of Medicine, and undergraduate degree from College of Arts & Sciences (TN).